GlassScriptPhysician profile
Jamie M Ewing
NPI 1437625340
$2,272.26
in general payments reported to CMS, 2019-2025
33 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.96 · 2022: $351 · 2023: $1,106 · 2024: $509 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.12 |
| Education | $465.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $316.41 | 2021-2023 | Verzenio, Jaypirca, Retevmo |
| Janssen Biotech, INC. | $303.30 | 2022-2025 | Carvykti, Darzalex, Tecvayli |
| Merck Sharp & Dohme LLC | $219.81 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $172.30 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $162.45 | 2023 | Imbruvica, Epkinly |
| Pfizer INC. | $104.09 | 2023-2024 | |
| Seagen INC. | $98.60 | 2023 | Padcev |
| Aveo Pharmaceuticals, INC. | $91.40 | 2024 | |
| Sanofi-Aventis U.S. LLC | $79.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $73.36 | 2023-2025 | Lynparza |
| Emd Serono, INC. | $54.70 | 2023-2024 | Bavencio |
| Glaxosmithkline, LLC. | $48.32 | 2023-2024 | Zejula |
| Gilead Sciences, INC. | $47.25 | 2022-2023 | Trodelvy |
| Genentech USA, INC. | $45.23 | 2022-2024 | Rozlytrek, Avastin, Alecensa |
| Beigene USA, INC. | $37.12 | 2022-2023 | Brukinsa |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $37.01 | 2022-2023 | Kyprolis |
| Myriad Genetic Laboratories, INC. | $32.03 | 2022-2023 | Precisetumor |
| Celgene Corporation | $29.84 | 2023-2024 | Reblozyl, Pomalyst |
| Astellas Pharma US INC | $28.98 | 2024 | Xtandi |
| Regeneron Healthcare Solutions, INC. | $27.71 | 2022 | |
| Mirati Therapeutics, INC. | $26.26 | 2023 | Krazati |
| Stemline Therapeutics INC. | $25.81 | 2025 | Elzonris |
| Immunocore Limited | $24.17 | 2024 | Kimmtrak |
| Eisai INC. | $22.54 | 2024 | |
| Genzyme Corporation | $20.18 | 2024 | |
| Pharmacosmos Therapeutics INC. | $19.61 | 2023 | Monoferric |
| Array Biopharma INC | $19.45 | 2023 | Lorbrena, Braftovi |
| Argenx US, INC. | $19.22 | 2023 | Vyvgart |
| Deciphera Pharmaceuticals INC. | $18.88 | 2024 | Qinlock |
| Abbvie INC. | $18.13 | 2024 | |
| Sobi, INC | $17.88 | 2023 | |
| Alexion Pharmaceuticals, INC. | $15.89 | 2023 | Ultomiris |
| Adc Therapeutics America, INC. | $15.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Ewing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.